It’s only fair to share… Elacestrant (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol (6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol FDA 1/27/2023, Orserdu WeightAverage: 458.646Monoisotopic: 458.293328472 Chemical FormulaC30H38N2O2 To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapyDrug Trials Snapshot Elacestrant, sold under the brand name Orserdu, is a selective estrogen receptor …